drugset / Trial / NCT04855526

THC + CBD and Memory Study

NCT04855526

Phase 0 Not yet recruiting 9 enrolled Hartford Hospital Yale University · collab
RandomizedCrossoverQuadruple-blindOther

Summary

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

Timeline

Start
2025-12-01
Primary completion
2026-12-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 50 mg
Subject delta-9-tetrahydrocannabinol Other / unclassified 65 mg

Indications